相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Somatic alterations and PD-L1 positivity in advanced breast cancer
Brian S. Finkelman et al.
CANCER RESEARCH (2022)
An automated tool to determine optimal cluster numbers in single-cell RNA sequencing data identifies key prognostic subsets of T cells in breast tumors
Siyao Liu et al.
CANCER RESEARCH (2022)
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
Richard D. Gelber et al.
EUROPEAN JOURNAL OF CANCER (2022)
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases
Gaia Griguolo et al.
NEURO-ONCOLOGY (2022)
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
Jens Huober et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
Maria Vittoria Dieci et al.
CELLS (2021)
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
Amrita Basu et al.
FRONTIERS IN IMMUNOLOGY (2021)
Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
Belen Blanco et al.
CLINICAL CANCER RESEARCH (2021)
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Aleix Prat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy
Carmine De Angelis et al.
CLINICAL CANCER RESEARCH (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Leisha A Emens et al.
LANCET ONCOLOGY (2020)
B cells, plasma cells and antibody repertoires in the tumour microenvironment
George Sharonov et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
Rim S. Kim et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer
Tiia J. Honkanen et al.
SCIENTIFIC REPORTS (2019)
High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer
Aura Muntasell et al.
CANCER IMMUNOLOGY RESEARCH (2019)
305OOverall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
L A Emens et al.
ANNALS OF ONCOLOGY (2019)
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+breast cancer
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2019)
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data
Tamara Diaz-Redondo et al.
FRONTIERS IN ONCOLOGY (2019)
Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer
Soizic Garaud et al.
JCI INSIGHT (2019)
NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival
Aura Muntasell et al.
CLINICAL CANCER RESEARCH (2019)
Tumor-associated macrophages: a short compendium
Hans Prenen et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2019)
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
Maria Vittoria Dieci et al.
SEMINARS IN CANCER BIOLOGY (2018)
Altered monocyte differentiation and macrophage polarization patterns in patients with breast cancer
Chih-Hsing Hung et al.
BMC CANCER (2018)
Tumor infiltrating lymphocytes in early breast cancer
Giancarlo Pruneri et al.
BREAST (2018)
Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC)
A Prat et al.
CANCER RESEARCH (2018)
Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype
Jeremy Force et al.
CLINICAL BREAST CANCER (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
P. Conte et al.
ANNALS OF ONCOLOGY (2018)
Targeting macrophages: therapeutic approaches in cancer
Luca Cassetta et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Natural killer cells and other innate lymphoid cells in cancer
Laura Chiossone et al.
NATURE REVIEWS IMMUNOLOGY (2018)
PolyI: C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors
Roxanne Charlebois et al.
CANCER RESEARCH (2017)
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
Stephen J. Luen et al.
LANCET ONCOLOGY (2017)
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2017)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature
Xixi Zhao et al.
ONCOTARGET (2017)
Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
Aura Muntasell et al.
FRONTIERS IN IMMUNOLOGY (2017)
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial
Shuzhen Liu et al.
JAMA ONCOLOGY (2017)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
The Emerging Role of B Cells in Tumor Immunity
Peiling Tsou et al.
CANCER RESEARCH (2016)
New Strategies in Breast Cancer: Immunotherapy
Lajos Pusztai et al.
CLINICAL CANCER RESEARCH (2016)
CIS is a potent checkpoint in NK cell-mediated tumor immunity
Rebecca B. Delconte et al.
NATURE IMMUNOLOGY (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
Edith A. Perez et al.
JAMA ONCOLOGY (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer
Satu Tiainen et al.
HISTOPATHOLOGY (2015)
Therapeutic cancer vaccines
Cornelis J. M. Melief et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31
Karen A. Gelmon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype
Meng Xu et al.
JOURNAL OF IMMUNOLOGY (2015)
Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery
Chandan Verma et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration
Tiziana Triulzi et al.
ONCOTARGET (2015)
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado et al.
JAMA ONCOLOGY (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Human breast cancer cells educate macrophages toward the M2 activation status
Sofia Sousa et al.
BREAST CANCER RESEARCH (2015)
Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer
Jashodeep Datta et al.
BREAST CANCER RESEARCH (2015)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Jason R. Brown et al.
CLINICAL CANCER RESEARCH (2014)
Macrophage Plasticity and Polarization in Liver Homeostasis and Pathology
Antonio Sica et al.
HEPATOLOGY (2014)
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja et al.
LANCET ONCOLOGY (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis
Yan Mao et al.
PLOS ONE (2014)
Prognostic significance of FOXP3+tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration
Shuzhen Liu et al.
BREAST CANCER RESEARCH (2014)
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
Elena Garcia-Martinez et al.
BREAST CANCER RESEARCH (2014)
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
Rizwan Romee et al.
BLOOD (2013)
Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer
Xiaoqiang Tang
CANCER LETTERS (2013)
Molecular determinants of trastuzumab efficacy: What is their clinical relevance?
Pradip De et al.
CANCER TREATMENT REVIEWS (2013)
Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients
Maria Libera Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail et al.
NATURE MEDICINE (2013)
CD4(+)T Cells: Differentiation and Functions
Rishi Vishal Luckheeram et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Macrophage plasticity and polarization: in vivo veritas
Antonio Sica et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Tumour-infiltrating macrophages and clinical outcome in breast cancer
S. M. A. Mahmoud et al.
JOURNAL OF CLINICAL PATHOLOGY (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hirokazu Matsushita et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Natural Innate and Adaptive Immunity to Cancer
Matthew D. Vesely et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29 (2011)
Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar M. A. Mahmoud et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
Sylvain Ladoire et al.
JOURNAL OF PATHOLOGY (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Macrophage Diversity Enhances Tumor Progression and Metastasis
Bin-Zhi Qian et al.
CELL (2010)
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Subhra K. Biswas et al.
NATURE IMMUNOLOGY (2010)
Regulatory T cells: how do they suppress immune responses?
Shimon Sakaguchi et al.
INTERNATIONAL IMMUNOLOGY (2009)
Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial
Heikki Joensuu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer
A. M. Al Murri et al.
BRITISH JOURNAL OF CANCER (2008)
TH 17 cells in development:: an updated view of their molecular identity and genetic programming
Chen Dong
NATURE REVIEWS IMMUNOLOGY (2008)
Exploring the full spectrum of macrophage activation
David M. Mosser et al.
NATURE REVIEWS IMMUNOLOGY (2008)
How regulatory T cells work
Dario A. A. Vignali et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2
Stefania Varchetta et al.
CANCER RESEARCH (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Immune surveillance of tumors
Jeremy B. Swann et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis
J Condeelis et al.
CELL (2006)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
The biology of human natural killer-cell subsets
MA Cooper et al.
TRENDS IN IMMUNOLOGY (2001)
Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood
H Jonuleit et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran et al.
NATURE (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
分享论文
